Agomab Therapeutics is preparing for a major debut on the U.S. public markets. On Thursday, the Belgium-based biotechnology firm announced its plans for an initial public offering (IPO) on the Nasdaq. The company aims for a total valuation of up to $828.5 million.
Agomab intends to raise approximately $212.5 million by offering 12.5 million American Depositary Shares (ADSs). Furthermore, the company expects to price these shares between $15 and $17 each.
A Specialized Pipeline for Crohn’s Disease
Agomab’s primary focus is the development of treatments for severe immune and inflammatory conditions. Specifically, they are targeting chronic fibrotic diseases.
The centerpiece of their clinical efforts is ontunisertib (AGMB-129). This candidate is an oral, gut-restricted ALK5 inhibitor. It is designed to treat fibrostenosing Crohn’s disease. This severe form of the illness causes inflammation-driven strictures, or narrowing of the intestines. Unfortunately, these strictures frequently lead to invasive surgeries for patients.
Financial Health and Biotech Market Trends
Like most clinical-stage biopharmaceutical companies, Agomab is currently prioritizing research over profitability.
- Net Loss Growth: For the nine months ending September 30, 2025, the company reported a net loss of €45.1 million (approx. $54 million). This represents an increase from the €34.5 million loss reported during the same period in 2024.
- Biotech IPO Revival: This move comes as the U.S. biotech IPO market shows signs of life. For instance, Eikon Therapeutics and Veradermics also filed to go public earlier this month. Stable market conditions have now accelerated this new wave of listings.
Key Listing and Underwriter Details
Agomab will trade under the ticker symbol “AGMB” on the Nasdaq Global Select Market. Because of the offering’s size, it is supported by a heavy-hitting roster of underwriters, including:
- J.P. Morgan
- Morgan Stanley
- Leerink Partners
- Van Lanschot Kempen
Armenian Dram
Ghana Cedi
Gambian Dalasi
Guinea Franc
Nigerian Naira
CFA Franc BEAC
